LICENSE AND SUPPLY AGREEMENT (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2009	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2013
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received	$ 60,000,000
Milestone payment received			25,000,000
Revenue recognized over designated period of relationship		4,600,000
Revenue recognition period		14 years
Protalix Bio Therapeutics Inc. [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage		40.00%
Collaboration Operation [Member]
Significant Accounting Policies [Line Items]
Accrued liabilities accrued related to the Collaboration Operation		7,100,000		8,000,000
Upon Filing of Pediatric Investigation Plan to EMA [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received	5,000,000
Upon FDAApproval [Member]
Significant Accounting Policies [Line Items]
Milestone payment received			$ 25,000,000